Lv12
100 积分 2023-04-09 加入
Efficacy of Ustekinumab Optimization by 2 Initial Intravenous Doses in Adult Patients With Severe Crohn’s Disease
3个月前
已完结
Bevacizumab and gastrointestinal perforations: a review from the FDA Adverse Event Reporting System (FAERS) database
4个月前
已完结
Ocrelizumab-related neutropenia: Effects of age, sex and bodyweight using the FDA Adverse Event Reporting System (FAERS)
4个月前
已完结
Tofacitinib in Acute Severe Ulcerative Colitis (TACOS): A Randomized Controlled Trial
4个月前
已完结
Efficacy and safety of upadacitinib maintenance therapy for moderately to severely active ulcerative colitis in patients responding to 8 week induction therapy (U-ACHIEVE Maintenance): overall results from the randomised, placebo-controlled, double-blind, phase 3 maintenance study
4个月前
已完结
Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn’s Disease
5个月前
已完结
Endoscopic scores for inflammatory bowel disease in the era of ‘mucosal healing’: Old problem, new perspectives
7个月前
已完结
The Natural History of Adult Crohn's Disease in Population-Based Cohorts
8个月前
已完结
Dietary factors and patterns in relation to risk of later‐onset ulcerative colitis in Chinese: A prospective study of 0.5 million people
8个月前
已完结
Editorial: Exploring the influence of diet on later‐onset ulcerative colitis—Are eggs and spicy foods the key factors in Asia?
8个月前
已关闭
皖公网安备34019202002308
